iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update

iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,030,000 shares, a drop of 5.6% from the February 13th total of 2,150,000 shares. Based on an average trading volume of 3,220,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 16.9% of the shares of the stock are sold short.

iBio Stock Performance

Shares of NYSEAMERICAN IBIO opened at $2.03 on Friday. iBio has a 52-week low of $0.36 and a 52-week high of $16.51. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.04.

iBio (NYSEAMERICAN:IBIO – Get Rating) last issued its quarterly earnings data on Tuesday, February 14th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter. iBio had a negative net margin of 2,054.97% and a negative return on equity of 106.69%. On average, equities research analysts anticipate that iBio will post -4.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IBIO. Millennium Management LLC bought a new position in shares of iBio in the second quarter valued at about $1,219,000. BlackRock Inc. increased its position in iBio by 71.7% in the third quarter. BlackRock Inc. now owns 6,799,636 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 2,838,918 shares during the period. Vanguard Group Inc. increased its position in iBio by 7.5% in the third quarter. Vanguard Group Inc. now owns 11,884,917 shares of the biotechnology company’s stock worth $2,024,000 after purchasing an additional 829,836 shares during the period. Renaissance Technologies LLC increased its position in iBio by 164.6% in the second quarter. Renaissance Technologies LLC now owns 1,151,377 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 716,295 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in iBio by 127.6% in the second quarter. Goldman Sachs Group Inc. now owns 293,743 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 164,664 shares during the period.

Analyst Upgrades and Downgrades

Separately, JMP Securities cut iBio from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 15th.

About iBio

(Get Rating)

iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins.